Glenmark Pharmaceuticals has announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa, India. The facility has been classified with a Voluntary Action Indicated (VAI) status. This classification indicates that the U.S. FDA has completed its inspection, and any identified observations are not considered to be of a serious nature that would prevent the facility from continuing its operations or exporting products.
FDA Inspection Concludes with VAI Classification
Glenmark Pharmaceuticals Ltd announced today that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility located in Goa, India. The inspection, which took place from June 22, 2026, to June 30, 2026, concluded with the facility receiving a Voluntary Action Indicated (VAI) status. This status signifies that the FDA has found no objectionable conditions or practices that would warrant mandatory enforcement action during the inspection.
Positive Regulatory Outcome
The VAI classification is generally viewed as a positive outcome for pharmaceutical manufacturers, indicating compliance with U.S. FDA regulations and facilitating the continued supply of products to the U.S. market. Glenmark Pharmaceuticals, a research-led, global pharmaceutical company, operates multiple manufacturing facilities worldwide. This particular facility in Goa plays a crucial role in its global supply chain. The company’s diverse portfolio spans respiratory, dermatology, and oncology, serving patients across 80+ countries.
The attached media release provides further details on this announcement and its implications for the company.
Source: BSE
